GlassScriptPhysician profile
Mackenzie Mapes
NPI 1083095251
$3,756.19
in general payments reported to CMS, 2019-2025
26 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.59 · 2023: $179 · 2024: $1,192 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,546.03 |
| Education | $195.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.22 | 2024-2025 | |
| Incyte Corporation | $448.77 | 2023-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $332.22 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $294.28 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $220.91 | 2025 | Otezla, Otezla |
| Pfizer INC. | $202.70 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $193.49 | 2023-2025 | Winlevi |
| Galderma Laboratories, L.P. | $183.78 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $183.28 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $146.76 | 2024 | Zoryve |
| Janssen Biotech, INC. | $133.06 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Leo Pharma INC. | $128.72 | 2024-2025 | Adbry, Anzupgo |
| Organon LLC | $123.83 | 2025 | Vtama, Nexplanon |
| Novartis Pharmaceuticals Corporation | $122.86 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.17 | 2023-2025 | Cabtreo, Arazlo, Duobrii |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $93.29 | 2024 | Vtama |
| Botanix Sb INC | $53.17 | 2025 | Sofdra |
| Ucb, INC. | $38.62 | 2025 | Bimzelx |
| Kerecis Limited | $37.74 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Kyowa Kirin, INC. | $36.96 | 2025 | |
| Convatec INC. | $21.94 | 2023 | |
| Almirall LLC | $16.91 | 2024 | Seysara |
| Hologic Sales and Service, LLC | $14.59 | 2021 | |
| Journey Medical Corporation | $14.35 | 2023 | |
| Strata Skin Sciences, INC. | $14.24 | 2025 | Xtrac |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Mapes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.